8-K: Pasithea Therapeutics Sets 2025 Annual Meeting Date and Shareholder Proposal Deadlines
Current Report Annual Meeting Date
Pasithea Therapeutics Corp. announced the date for its 2025 annual meeting of stockholders as September 3, 2025, and established deadlines for shareholder proposals and director nominations.
Summary
- The Board of Directors of Pasithea Therapeutics Corp. has set the 2025 annual meeting of stockholders for September 3, 2025.
- Proxy materials for the 2025 Annual Meeting are expected to be delivered and made available on or about July 24, 2025.
- This Current Report on Form 8-K was filed because the 2025 Annual Meeting will be held more than thirty (30) days after the anniversary date of the 2024 annual meeting, which requires the company to provide specific due dates for stockholder proposals and nominations.
- Stockholders intending to present proposals for inclusion in the proxy materials under Rule 14a-8 must ensure such proposals are received by the Company no later than July 21, 2025.
- Stockholders intending to solicit proxies in support of director nominees under the universal proxy rules (Rule 14a-19) must provide the required notice by July 21, 2025.
Sentiment
Score: 5
Explanation: The document is purely administrative, providing routine corporate governance updates without any positive or negative financial implications.
Future Outlook
The company expects to begin delivering and making available proxy materials for the 2025 Annual Meeting on or about July 24, 2025.
Management Comments
- The report was signed by Tiago Reis Marques, Chief Executive Officer.
Industry Context
This administrative filing is a standard corporate governance disclosure, common across publicly traded companies, ensuring transparency regarding shareholder meeting schedules and proposal deadlines.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Scheduling | The Board of Directors set the date for the 2025 annual meeting of stockholders for September 3, 2025. | 2025-07-10 | Establishes the formal date for the annual shareholder gathering, crucial for corporate oversight and shareholder engagement. |
| Shareholder Proposal Deadlines | Established new deadlines for shareholder proposals under Rule 14a-8 and director nominations under Rule 14a-19 due to the annual meeting being held more than 30 days after the prior year's anniversary. | 2025-07-10 | Ensures compliance with SEC regulations for shareholder participation in the proxy process, providing clear timelines for submissions. |
Stakeholder Impact
- Shareholders: Provided with clear deadlines for submitting proposals and director nominations for the upcoming annual meeting, ensuring their participation rights are maintained.
Next Steps
- Delivery and availability of proxy materials for the 2025 Annual Meeting on or about July 24, 2025.
- Receipt of qualified stockholder proposals under Rule 14a-8 by July 21, 2025.
- Receipt of notice for director nominees under Rule 14a-19 by July 21, 2025.
- Holding of the 2025 Annual Meeting of stockholders on September 3, 2025.
Key Dates
| Date | Description |
|---|---|
| 2025-07-10 | Date of earliest event reported; Board of Directors set the date for the 2025 annual meeting of stockholders. |
| 2025-07-11 | Date the Form 8-K was signed by the Chief Executive Officer. |
| 2025-07-21 | Deadline for stockholders to submit proposals for inclusion in proxy materials under Rule 14a-8. |
| 2025-07-21 | Deadline for stockholders to provide notice for director nominees under Rule 14a-19 (universal proxy rules). |
| 2025-07-24 | Approximate date the Company expects to begin delivering and making available proxy materials for the 2025 Annual Meeting. |
| 2025-09-03 | Date of the Company's 2025 annual meeting of stockholders. |
Keywords
Pasithea Therapeutics, KTTA, SEC Filing, Form 8-K, Annual Meeting, Shareholder Meeting, Proxy Materials, Shareholder Proposals, Director Nominations, Corporate Governance, Rule 14a-8, Rule 14a-19, Nasdaq Capital Market
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.